What European Cannabis Importers Actually Look For in a New Supplier

Legal supply is only the first question

International suppliers often begin with the evidence they know best: cultivation capacity, certificates, cannabinoid profiles and an ex-works price. Those points matter. But they do not answer the buyer’s main commercial question: can this particular product be supplied consistently, lawfully and profitably through the intended route in the target country?

That distinction matters because Europe is not one cannabis market. Medical cannabis, authorised pharmaceutical products, industrial hemp, consumer cannabinoid products and adult-use cannabis sit in different legal and commercial frameworks. Even within medical supply, the route may depend on national medicines, narcotics, import, prescribing and pharmacy rules. A permission or product status in the country of origin does not automatically transfer to an EU/EEA country.

This article focuses primarily on regulated medical and pharmaceutical cannabis supply chains. It is not a universal legal checklist. It describes the practical questions that a serious importer, distributor or pharmaceutical supply-chain partner is likely to test before allocating regulatory effort, working capital and market credibility to a new supplier. Companies still need product- and country-specific advice before committing to a route.

1. Product fit comes before product availability

A buyer is not simply asking whether you can grow or manufacture cannabis. They are asking whether what you produce solves a defined need in their market. That starts with the product category, intended use, dosage form, specifications, pack configuration and the route through which it can legally reach the end customer or patient.

For medical cannabis, a commercially relevant assessment may include whether the cannabinoid profile, format and quality specification fit the buyer’s existing portfolio and the target market’s prescribing or preparation practices. For an authorised pharmaceutical product, the applicable marketing-authorisation and supply arrangements are different. Industrial hemp raw material, a CBD food, a cosmetic ingredient and cannabis intended for a non-commercial adult-use framework cannot be treated as interchangeable routes.

A long catalogue can therefore be less persuasive than a focused proposition. The useful supplier explains which product is intended for which country, buyer type and channel; what evidence supports that fit; and what must still be resolved. Our overview of the European cannabis market and the Cannabis Market Entry Europe framework provide wider context for that selection work.

2. Documentation must match the actual regulatory route

For medicinal products intended for the EU market, manufacturing and importation sit within the EU medicines framework. The European Medicines Agency states that manufacturers of medicines for the EU market must comply with EU good manufacturing practice regardless of where they are located. For medicinal products within the scope of the EU medicines framework, EU legislation requires appropriate authorisation for manufacture and for importation from third countries. For imported batches of such medicinal products, Qualified Person certification and batch release responsibilities apply before release within the EU/EEA supply chain. That pathway follows the applicable EU pharmaceutical framework and product classification; it should not be assumed to apply identically to every cannabis product or national supply route.

Those concepts are related but not interchangeable. GMP governs manufacturing quality systems. EMA’s GACP guideline addresses agricultural and collection practices for herbal starting materials. GDP concerns the wholesale distribution of medicinal products. A national import authorisation permits defined activities; it does not replace GMP evidence, product classification, batch certification or any marketing-authorisation or national supply requirements that apply to the product.

The practical buyer question is therefore not ‘Do you have a certificate?’ but ‘Does the full evidence package support this product, this manufacturing chain and this import route?’ Depending on the case, review may extend to licences, inspection status, quality agreements, certificates of analysis, validated methods, stability information, contaminant controls, batch records, change-control procedures, complaints and recall processes. The exact package is product- and jurisdiction-specific; not every item applies to every cannabis category.

• What is the product’s intended classification in the target country?
• Which party holds each required manufacturing, import, wholesale or product authorisation?
• Where will testing, QP certification and batch release take place when required?
• Which records can the supplier provide during qualification and for each batch?
• How are deviations, specification changes, complaints and recalls managed?

3. GMP readiness is operational, not presentational

A logo on a certificate does not tell a partner how reliably the quality system performs. A pharmaceutical importer will usually need to understand the authorised scope, relevant site and activities, recent inspection position, testing arrangements, technical agreements and the responsibilities assigned across the chain. Where third-country manufacture is involved, EudraLex Annex 21 and Annex 16 are central references for importation and QP certification of medicinal products.

GACP and GMP also should not be collapsed into one label. GACP can be relevant upstream to herbal starting materials, depending on the material, production stage and regulatory route, while GMP applies to the medicinal-product manufacturing activities within scope. The transition between cultivation, primary processing and pharmaceutical manufacture must be defined for the specific process and accepted regulatory route. A supplier should be able to describe that boundary accurately rather than using ‘EU-GMP ready’ as a broad marketing phrase.

Commercially, readiness means that the supplier can survive detailed qualification without creating repeated uncertainty. Clear ownership, current documents, traceable answers and realistic timelines reduce the importer’s execution risk. Gaps do not always end a discussion, but undisclosed gaps usually damage confidence.

4. Reliability is part of the product

An approved specification has limited value if supply repeatedly misses it. Buyers are likely to test whether capacity claims translate into dependable batches, predictable lead times and continuity under normal operational pressure. They may examine historical batch consistency, production planning, release timelines, deviation rates, reserve capacity, critical suppliers and contingency plans.

This is where attractive samples can mislead both sides. A hand-selected sample may demonstrate potential, but the commercial proposition depends on repeatability at the required volume. The importer must plan orders, cash flow, regulatory work, logistics and customer commitments around actual production and release performance.

Realistic minimum order quantities matter too. An MOQ that works for the producer may be too large for an importer testing demand in one country. An MOQ that is commercially convenient for a small launch may be uneconomic for the supplier. The right question is whether both parties can design an initial volume, replenishment cycle and scale-up path that match credible demand rather than optimistic forecasts.

• Consistent specifications and suitable batch quality
• Credible capacity and continuity of supply
• Predictable production, testing and release lead times
• Realistic minimum orders and replenishment terms
• Prompt communication when a batch, document or shipment changes

5. Price must work through the whole chain

An attractive ex-works price is not the same as an attractive European commercial proposition. The relevant calculation continues through freight and security arrangements, import and customs handling where applicable, testing, quality and regulatory work, insurance, financing, warehousing, importer and distributor economics, and the pharmacy, retail or other downstream channel. Taxes and reimbursement conditions may also matter, depending on the product and country.

Supplier price → logistics and import costs → regulatory and quality costs → importer or distributor economics → downstream economics → final market price.

There is no responsible universal margin percentage for this chain. The structure changes by country, product classification, contract and channel. What matters is whether each necessary participant can perform its role, carry its risk and earn a viable return while the final price remains acceptable in the intended market.

This is why low cultivation cost alone rarely settles the decision. A cheaper batch that creates extra testing, unpredictable release, write-offs, stock gaps or excessive working-capital exposure may be commercially inferior to a more expensive but dependable supply. The buyer is evaluating total landed and operational economics, not only the supplier’s invoice.

6. Specifications, packaging and change control affect market access

A buyer needs an agreed product, not a moving target. The commercial and quality teams should be able to work from controlled specifications covering the attributes relevant to the product: identity, strength or cannabinoid content, microbiological and contaminant limits, moisture or other stability-related parameters, packaging materials, pack sizes, labelling inputs and storage conditions. The applicable requirements depend on classification and market.

Batch consistency matters because every unexplained variation can create work downstream. A change to genetics, cultivation inputs, processing, test methods, manufacturing site, packaging or specification may affect qualification, stability evidence, quality agreements or national filings. Serious partners therefore assess not only the current batch but the supplier’s change-control discipline.

Packaging should be considered early. A bulk format that is efficient at origin may not fit the importer’s authorised operations or the downstream pack configuration. Responsibilities for artwork, language, tamper evidence, serialisation where applicable, samples, reference standards and retention materials must be allocated rather than assumed.

7. Market selection changes the supplier proposition

Approaching ‘Europe’ as one opportunity usually produces vague discussions. The same supplier may face a different product route, authority, buyer structure and commercial role in each country. Industry Intelligence should therefore come before broad distributor outreach.

Germany illustrates a developed but specific medical route governed by the Medizinal-Cannabisgesetz, separate from the country’s non-commercial adult-use rules. Its scale of activity does not make it the automatic first market for every supplier: portfolio fit, competition, pricing, partner access and regulatory change still determine viability. See the Germany market-entry page for the strategic context.

Portugal demonstrates why ‘market’ can mean several things. INFARMED separately licenses cultivation, manufacture, wholesale distribution, import and export activities for medical, veterinary-medical or research purposes. A licensed production and export base is not the same proposition as a large domestic demand market, and Portugal should not be described as a universal gateway without examining the actual licensed activities and destination requirements.

Spain provides another distinct example. Its 2025 framework for standardised cannabis preparations establishes a pharmacy-linked medical route with product registration requirements administered by AEMPS. That route is different from Germany’s, and it is separate from Spain’s legally contested non-commercial cannabis-club context. These examples are not a country ranking. They show why the supplier proposition must be rebuilt around the target market and product classification.

8. Importers assess the working relationship as well as the product

A new supply relationship creates work before it creates revenue. The importer may need to qualify the site, review records, negotiate quality and supply agreements, coordinate testing and release, obtain permissions, prepare the market and carry inventory risk. It will therefore evaluate whether the supplier behaves like a long-term operating partner.

Professional responsiveness is not cosmetic. Slow or incomplete answers can delay due diligence and signal how future deviations or shortages may be handled. Commercial discipline includes named decision-makers, realistic commitments, version-controlled documents, agreed response times and direct escalation when something goes wrong.

Responsibility must also be explicit. The distributor should not be expected to solve every regulatory, quality and market issue after signature. A credible plan defines who owns product classification, licences, audits, testing, release, import certificates, logistics, forecasting, customer development, pharmacovigilance where applicable, and ongoing regulatory monitoring. The allocation will differ by product and contract, but ambiguity is itself a risk.

Common mistakes when approaching European partners

The following are recurring commercial weaknesses rather than universal rules. Any one of them can make a technically capable supplier difficult to progress because it transfers unresolved work and risk to the prospective partner.

• Leading with a country-of-origin story instead of a target-market proposition
• Assuming approval, legality or certification in one jurisdiction transfers automatically to another
• Focusing on cultivation cost while ignoring landed cost and downstream economics
• Sending a broad catalogue without identifying the relevant product, buyer and channel
• Setting price expectations before mapping regulatory, quality, logistics and distribution costs
• Providing incomplete, inconsistent or outdated technical documentation
• Offering specifications that cannot be reproduced reliably across commercial batches
• Seeking national or multi-country exclusivity before demonstrating operational and commercial fit
• Expecting the distributor to own every regulatory, import and market-development task
• Contacting partners across several countries without understanding each route to market

A practical readiness test

Before approaching European medical cannabis importers, narrow the discussion to one product and one target route. If the following questions cannot be answered clearly, the supplier may be early for a serious commercial conversation.

• What is the intended product classification and legal supply route in the target country?
• Which customer, patient, pharmacy, manufacturer or other buyer need does the product address?
• Which licences and authorisations are required, and which party will hold each one?
• Does the manufacturing and quality evidence cover the actual product, site and activities?
• Can commercial batches repeatedly meet the agreed specification?
• What are credible production, testing, release and delivery lead times?
• Can minimum orders and replenishment terms support a realistic launch?
• Does pricing remain viable after every necessary cost and margin in the chain?
• Who owns regulatory, quality, logistics, forecasting and market-development tasks?
• What happens if demand changes, a batch is delayed or a specification must change?

What this means in practice

The strongest supplier proposition is not ‘we can legally export cannabis’. It is a documented plan showing that a defined product can be qualified, imported, released, distributed and sold through one target market with dependable operations and workable economics.

That requires market selection before partner selection, and commercial modelling alongside regulatory work. Canna Euro Consulting helps international companies assess market entry, distribution strategy, market selection and commercial readiness before they commit to a European route. The Market Entry Calculator can provide an initial structured assessment; a direct discussion is more appropriate where product classification, partner responsibilities or supply-chain economics need deeper review.